Numinus Wellness - Founder & CEO, Payton Nuquvest
Founder & CEO, Payton Nuquvest
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Numinus Wellness Inc. (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic
  • It is in the Plateau neighbourhood and will have an expanded capacity to offer ketamine treatments
  • Expanded services will include different administrations of ketamine
  • New services will include the option to access ketamine as a standalone treatment
  • Numinus Wellness Inc. (NUMI) is down 3.64 per cent, trading at $0.26 per share as of 1:27 p.m. ET

Numinus Wellness (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic.

The new site is in the Plateau neighbourhood and will have an expanded capacity to offer ketamine treatments, including a wider assortment of ketamine-assisted therapy options.

Jason Lapensee, Numinus Senior Vice President of Clinical Operations, commented,

“There is significant research showing ketamine can be highly effective in treating depression, addiction, trauma and anxiety, and other common mental health disorders.”

Expanded services will include different administrations of ketamine such as Spravato, intramuscular, lozenge, and nasal spray, along with options in treatment length and session type.

The company’s current offering includes a six-week ketamine-assisted therapy program for indications including depression, addiction, trauma, and anxiety.

 New services will include the option to access ketamine as a standalone treatment to allow clients to use it before ketamine-assisted therapy, as an emergency antidepressant, or with therapy from an external health provider.

 Additionally, Numinus will continue to support access for clients in need through the federal Special Access Program with areas designated for psilocybin- and MDMA-assisted therapies.

Payton Nyquvest, Numinus Founder and CEO stated,

“Expanding our services here is another important step towards improving access to best-in-class and innovative mental healthcare in Quebec while continuing to expand our clientele and market presence.”

Numinus Wellness Inc. (NUMI) is down 3.64 per cent, trading at $0.26 per share as of 1:27 p.m. ET.


More From The Market Herald
VitalHub

" VitalHub (TSX:VHI) announces multi year contract with NHS Mid and South Essex ICB

VitalHub (VHI) announced a multi-year licensing contract with NHS Mid and South Essex Integrated Care Board (Essex).
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.